HPV, Cytology, and Cotest Cervical Cancer Screening and the Risk of Precancer
JAMA Network Open · 2026
DOI: 10.1001/jamanetworkopen.2026.1304 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, 2026. Verfasst von Anna Gottschlich und 13 weiteren Autor:innen. Beteiligte Einrichtung: Women's Health Research Institute, BC Women's Hospital and Health Services, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Early Detection of Cancer, Papillomavirus Infections, Precancerous Conditions, Uterine Cervical Dysplasia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance There is a global call to end cervical cancer, and various jurisdictions are still determining optimal strategies to accelerate elimination. Human papillomavirus (HPV)-negative testing confers lower risk of future precancer vs normal cytology; high-quality longitudinal data are needed comparing risk after a negative HPV test vs negative cotest (HPV and cytology).
Objective
To compare long-term risk of cervical precancer based on HPV, cytology, and cotest screening results. Design, Setting, and Participants This cohort study linked data from a randomized clinical trial to a comprehensive screening program in British Columbia. Participants were recruited between 2006 and 2012 and followed from trial exit to 10 years postexit. Eligible participants were women who completed trial exit cotesting. Data were analyzed between January and April 2025. Exposure HPV and cytology status from exit cotesting were considered, stratified by status of each test. Main Outcome and Measures Cumulative risk of precancer was calculated over follow-up using Kaplan-Meier techniques. Risk was compared among groups who tested HPV-negative with normal cytology, HPV-negative with abnormal cytology, HPV-positive with normal cytology, and HPV-positive with abnormal cytology. Additionally, risk among those who were HPV-negative (regardless of cytology result), with normal cytology (regardless of HPV results), or were cotest negative were compared in order to simulate outcomes in primary HPV screening, cytology, and cotest programs, respectively.
Results
In this cohort of 8078 women (median [IQR] age at exit screen, 49 [41-57] years; 1636 Asian [22.4%], 223 Indigenous [3.0%], 5568 White [76.1%]) who participated in a British Columbia–based cervical cancer screening trial, the HPV-positive with abnormal cytology group had the highest cumulative incidence risk (CIR) of cervical intraepithelial neoplasia grade 2 or higher at the end of follow-up (CIR, 43.47%; 95% CI, 23.45%-58.26%), followed by the HPV-positive and cytology-negative group (CIR, 22.21%; 95% CI, 11.49%-31.62%). The HPV-negative with abnormal cytology (CIR, 4.83%; 95% CI, 0%-10.03%) and the HPV-negative with normal cytology (CIR, 0.37%; 95% CI, 0.13%-0.60%) groups had significantly lower CIR at the end of follow-up. Less than 1% of the population was HPV-negative with abnormal cytology (69 of 8078 [0.85%]). Women who were HPV-negative regardless of cytology results (CIR, 0.41%; 95% CI, 0.17%-0.65%) had a similar risk as those who cotested negative (CIR, 0.37%; 95% CI, 0.13%-0.60%); both groups had lower risk than those with normal cytology results (regardless of HPV result) (CIR, 1.28%; 95% CI, 0.78%-1.78%) throughout follow-up. Conclusions and Relevance In this cohort study of cervical cancer screen testing approaches and risk of cervical precancer, after a negative HPV test (regardless of cytology results) risk of precancer remained acceptably low throughout long-term follow-up. This suggests that cotesting yielded limited benefits, while increasing costs, relative to primary HPV testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Women's Health Research Institute, BC Women's Hospital and Health Services, Vancouver, British Columbia, Canada.
- Department of Oncology, Wayne State University, Detroit, Michigan.
- Population Sciences and Disparities Research Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan.
- Population Health Sciences, BC Cancer, Vancouver, British Columbia, Canada.
- Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
- British Columbia Cervix Screening Program, BC Cancer, Vancouver, British Columbia, Canada.
Zitieren
APA
Gottschlich, A., Smith, L. W., Hong, Q., Dabee, S., Gondara, L., Cook, D., Martin, R. E., Melnikow, J., Peacock, S., Proctor, L., Stuart, G., Franco, E. L., Krajden, M., & Ogilvie, G. S. (2026). HPV, Cytology, and Cotest Cervical Cancer Screening and the Risk of Precancer. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2026.1304
Vancouver
Gottschlich A, Smith LW, Hong Q, Dabee S, Gondara L, Cook D, et al. HPV, Cytology, and Cotest Cervical Cancer Screening and the Risk of Precancer. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2026.1304
BibTeX
@article{Gottschlich2026,
author = {Gottschlich, Anna and Smith, Laurie W and Hong, Quan and Dabee, Smritee and Gondara, Lovedeep and Cook, Darrel and Martin, Ruth Elwood and Melnikow, Joy and Peacock, Stuart and Proctor, Lily and Stuart, Gavin and Franco, Eduardo L and Krajden, Mel and Ogilvie, Gina S},
title = {HPV, Cytology, and Cotest Cervical Cancer Screening and the Risk of Precancer},
journal = {JAMA Network Open},
year = {2026},
doi = {10.1001/jamanetworkopen.2026.1304}
}
EUVIMED